Two vaccines developed in China show efficacy against enterovirus 71 (EV71), the major cause of hand, foot, and mouth disease or herpangina. Two randomized, double-blind, placebo-controlled trials involved 10,007 (healthy children 6 to 35 months of age) and 12000 (healthy children 6 to 71 months of age), respectively, showed 94.8% to 97.4% efficacy according to the intention-to-treat analysis. The safety profile was comparable to placebo in one trial and having fever more common in the vaccine group in another trial. 中国开发的两种疫苗显示对肠道病毒71型（EV71）有效，该病毒为手，足，口病的主要病因。两项随机，双盲，安慰剂对照试验分别包括10,007名（月龄6〜35）和12000名（月龄6〜71）健康儿童，根据意向性治疗分析结果显示有效率高达94.8％至97.4％。其中一项试验疫苗的安全性与安慰剂相似，而另一项试验中发热在疫苗组更常见。
